热门资讯> 正文

Avalyn Pharma报告第一季度业绩

2026-06-03 19:39

Avalyn Pharma(AVLN) 0

Avalyn Pharma press release (AVLN): Q1 net loss was $26.9 million for the first quarter of 2026, as compared to $17.5 million for the first quarter of 2025.
Cash, cash equivalents, and marketable securities were $123.1 million as of March 31, 2026.

More on Avalyn Pharma Inc.

Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline
Lung disease drug developer Avalyn surges on public debut
Avalyn Pharma prices $300M IPO at $18 per share
Historical earnings data for Avalyn Pharma Inc.
Financial information for Avalyn Pharma Inc.

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。